San FranciscoFounded 20236+ employeesPrivate
$13.5M raisedSeed· last: seed (May 2026)· 3 rounds
Backed by(11 investors)
ParcelBio is engineering a new class of mRNA medicines designed to deliver unprecedented potency and durability. Its proprietary APEXm™ platform uses novel RNA domains to enhance protein expression and extend activity, enabling therapies that reach the thresholds required for meaningful, and potentially curative, clinical outcomes. The company is advancing programs in autoimmune disease, oncology, and encoded protein therapeutics.
